Reporting Matters: Severe Adverse Events in Soft Tissue Sarcoma Therapy-A 30-Year Systematic Review of Placebo- and Non-Systemic-Controlled Randomized Trials.

ABSTRACT: Background: Systemic therapy for soft tissue sarcoma (STS) provides modest survival benefit but carries clinically relevant toxicity. Published trials report adverse events (AEs) of varying quality and extension. Poor toxicity reporting hampers balanced risk-benefit appraisal. Methods: A PRISMA-2020 systematic review was registered in PROSPERO CRD420251087366. PubMed, CENTRAL, and Google Scholar were searched from 16 December 2024 to 16 April 2025 for randomized controlled trials (RCTs) evaluating chemotherapy, kinase inhibitors, or immune checkpoint inhibitors in STS. AE terms were harmonized to CTCAE v5.0; event rates were normalized to patients evaluable for safety. Pooled proportions used DerSimonian-Laird random-effects models; between-group comparisons employed unpaired

SUBMITTER: Aeschbacher R 

PROVIDER: S-EPMC12524033 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature